Present and future treatment of pancreatic cancer.
Gemcitabine has become a new standard for treatment of advanced pancreatic cancer. This development is based not only on drug efficacy but also on a favorable side-effect profile. Combinations of gemcitabine with antitumor drugs such as cisplatin, 5-fluorouracil, docetaxel, irinotecan, oxaliplatin, or capecitabine, and biological agents such as cetuximab or trastuzumab, have yielded promising results in phase II trials. However, none of these combinations has yet reached the level of an evidence-based standard treatment.
Heinemann
Volker
V
Department of Hematology/Oncology, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077143:Docetaxel; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D017239:Paclitaxel; D005472:Fluorouracil; D000093542:Gemcitabine